KNBIF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Sep 3 closing price
Capitalization
4.81M
SPHDF
Price
$18.40
Change
+$3.65 (+24.75%)
Updated
Jul 28 closing price
Capitalization
229M
Interact to see
Advertisement

KNBIF vs SPHDF

Header iconKNBIF vs SPHDF Comparison
Open Charts KNBIF vs SPHDFBanner chart's image
Kane Biotech
Price$0.03
Change-$0.00 (-0.00%)
Volume$1.65K
Capitalization4.81M
Santhera Pharmaceuticals Holdings
Price$18.40
Change+$3.65 (+24.75%)
Volume$600
Capitalization229M
KNBIF vs SPHDF Comparison Chart in %
Loading...
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KNBIF vs. SPHDF commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNBIF is a Hold and SPHDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (KNBIF: $0.03 vs. SPHDF: $18.40)
Brand notoriety: KNBIF and SPHDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNBIF: 33% vs. SPHDF: 124%
Market capitalization -- KNBIF: $4.81M vs. SPHDF: $229M
KNBIF [@Biotechnology] is valued at $4.81M. SPHDF’s [@Biotechnology] market capitalization is $229M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNBIF’s FA Score shows that 1 FA rating(s) are green whileSPHDF’s FA Score has 1 green FA rating(s).

  • KNBIF’s FA Score: 1 green, 4 red.
  • SPHDF’s FA Score: 1 green, 4 red.
According to our system of comparison, SPHDF is a better buy in the long-term than KNBIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KNBIF’s TA Score shows that 4 TA indicator(s) are bullish while SPHDF’s TA Score has 2 bullish TA indicator(s).

  • KNBIF’s TA Score: 4 bullish, 3 bearish.
  • SPHDF’s TA Score: 2 bullish, 1 bearish.
According to our system of comparison, KNBIF is a better buy in the short-term than SPHDF.

Price Growth

KNBIF (@Biotechnology) experienced а +3.75% price change this week, while SPHDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPHDF($229M) has a higher market cap than KNBIF($4.81M). SPHDF has higher P/E ratio than KNBIF: SPHDF (2.53) vs KNBIF (1.07). SPHDF YTD gains are higher at: 95.329 vs. KNBIF (-63.188).
KNBIFSPHDFKNBIF / SPHDF
Capitalization4.81M229M2%
EBITDA-3.7MN/A-
Gain YTD-63.18895.329-66%
P/E Ratio1.072.5343%
Revenue2.44MN/A-
Total Cash494KN/A-
Total Debt2.08MN/A-
FUNDAMENTALS RATINGS
KNBIF vs SPHDF: Fundamental Ratings
KNBIF
SPHDF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6539
P/E GROWTH RATING
1..100
9312
SEASONALITY SCORE
1..100
1419

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KNBIF's Valuation (28) in the null industry is in the same range as SPHDF (59). This means that KNBIF’s stock grew similarly to SPHDF’s over the last 12 months.

KNBIF's Profit vs Risk Rating (100) in the null industry is in the same range as SPHDF (100). This means that KNBIF’s stock grew similarly to SPHDF’s over the last 12 months.

KNBIF's SMR Rating (100) in the null industry is in the same range as SPHDF (100). This means that KNBIF’s stock grew similarly to SPHDF’s over the last 12 months.

SPHDF's Price Growth Rating (39) in the null industry is in the same range as KNBIF (65). This means that SPHDF’s stock grew similarly to KNBIF’s over the last 12 months.

SPHDF's P/E Growth Rating (12) in the null industry is significantly better than the same rating for KNBIF (93). This means that SPHDF’s stock grew significantly faster than KNBIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KNBIFSPHDF
RSI
ODDS (%)
Bearish Trend 4 days ago
65%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
33%
Momentum
ODDS (%)
Bullish Trend 4 days ago
66%
N/A
MACD
ODDS (%)
Bullish Trend 4 days ago
71%
Bearish Trend 4 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
58%
Bullish Trend 4 days ago
12%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
14%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
75%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
18%
View a ticker or compare two or three
Interact to see
Advertisement
KNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIJYX34.490.61
+1.80%
Fidelity Advisor Biotechnology Z
RALYX10.750.05
+0.47%
Lazard Real Assets R6
GOIOX33.220.14
+0.42%
JHancock International Growth 1
TGVFX56.30-0.15
-0.27%
Touchstone Dynamic Large Cap Growth A
MNNCX38.95-0.11
-0.28%
Victory Munder Multi-Cap C

KNBIF and

Correlation & Price change

A.I.dvisor tells us that KNBIF and CADL have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KNBIF and CADL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNBIF
1D Price
Change %
KNBIF100%
N/A
CADL - KNBIF
22%
Poorly correlated
+2.15%
LQDA - KNBIF
21%
Poorly correlated
+0.03%
SPHDF - KNBIF
20%
Poorly correlated
N/A
MMIRF - KNBIF
12%
Poorly correlated
N/A
IPHYF - KNBIF
6%
Poorly correlated
N/A
More

SPHDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPHDF has been closely correlated with TRML. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if SPHDF jumps, then TRML could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHDF
1D Price
Change %
SPHDF100%
N/A
TRML - SPHDF
78%
Closely correlated
+6.53%
COGT - SPHDF
63%
Loosely correlated
+0.85%
MEOBF - SPHDF
50%
Loosely correlated
N/A
KROS - SPHDF
38%
Loosely correlated
+0.26%
CYTOF - SPHDF
35%
Loosely correlated
N/A
More